Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

Sandoz, Viatris Look To Be In Commercial Vanguard; Supply Core, CDMOs Vital

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Generics producers are keen for a piece of the GLP-1 pie

With the addition of weight loss and obesity indications and more patient-friendly dosing regimens beginning at the start of the current decade, glucagon-like-peptide-1 (GLP-1) receptor agonists have exploded into a multi-billion-dollar, cultural phenomenon, comparable in the prescription pharma space to the arrival of Viagra (sildenafil) in the late 1990s or Botox before it.

More from Outlook

More from Growth